Private Placement

A new national reimbursement code for NeurAxis's IB-Stim therapy is set to revolutionize access for chronic GI pain patients, validating the technology.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

Eurythmics legend Dave Stewart launches a new venture builder to give artists control over their IP and revenue. But can this "creativity-first" model work?

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

After a major win at CES 2026, a South Korean edtech firm is set to bring its revolutionary 'Visual LLM' learning platform to the US K-12 market.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

At CES 2026, RobotEra's L7 humanoid and 'Hexa-Core' lineup showcase China's growing dominance in the global robotics race. Here's a deep dive.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Rebranded and recapitalized, Future Mineral Resources is raising $4.5M to advance its gold, uranium, and nickel projects across three continents.

Sana Biotechnology prepares for its pivotal J.P. Morgan update, balancing groundbreaking diabetes data against a ticking financial clock and fierce competition.

With major institutional backing, a fast-growing lender is financing a new generation of upscale, affordable manufactured homes to tackle the housing crisis.

The oversubscribed fund nearly doubles its predecessor, signaling strong investor confidence in using private credit to empower millions in emerging markets.

MIT's top AI conference shifts focus from pilots to enterprise-wide adoption, tackling trust, security, and the rise of the 'agentic workforce'.

With AI projected to cut search traffic by 50%, a new battle for online visibility is here. Clicks are out, and AI citations are the new currency.

After a multi-year slump, investors poured nearly $14 billion into cybersecurity in 2025, driven by AI risks and the relentless growth of cybercrime.

A biotech firm's promising concussion therapy, backed by NFL's Alex Smith, shows an 85% responder rate and now seeks public funding for its final push.

At CES 2026, an ice cream-scooping robot reveals PaXini's full-stack plan to solve embodied AI's biggest challenges with advanced tactile sensors and data.